Literature DB >> 18804044

HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.

Ricardo Pasquini1, Jeanette Carreras2, Marcelo C Pasquini2, Bruce M Camitta3, Anders L Fasth4, Gregory A Hale5, Richard E Harris6, Judith C Marsh7, Anibal J Robinson8, Mei-Jie Zhang2, Mary Eapen9, John E Wagner10.   

Abstract

Related to the underlying DNA repair defect that is the hallmark of Fanconi anemia (FA), preparatory regimen-related toxicities have been obstacles to hematopoietic cell transplantation (HCT). In an attempt to decrease the risk and severity of regimen-related toxicities, nonirradiation regimens have been explored. The aim of this study is to compare outcomes after irradiation and nonirradiation regimens in 148 FA patients and identify risk factors impacting upon HCT outcomes. Hematopoietic recovery, acute and chronic graft-versus-host disease (aGVHD, GVHD), and mortality were similar after irradiation and nonirradiation regimens. In both groups of recipients aged >10 years, prior use of androgens and cytomegalovirus seropositivity in either the donor or recipient were associated with higher mortality. With median follow-ups >5 years, the 5-year probability of overall survival, adjusted for factors impacting overall mortality was 78% and 81% after irradiation and nonirradiation regimens, P = .61. In view of the high risk of cancer and other radiation-related effects on growth and development, these results support the use of nonirradiation preparatory regimens. As the peak time for developing solid tumors after HCT is 8 to 9 years, longer follow-up is required before definitive statements can be made regarding the impact of nonirradiation regimens on cancer risk.

Entities:  

Mesh:

Year:  2008        PMID: 18804044      PMCID: PMC2581414          DOI: 10.1016/j.bbmt.2008.06.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  20 in total

Review 1.  Pathophysiology and treatment of graft-versus-host disease.

Authors:  M E Flowers; E Kansu; K M Sullivan
Journal:  Hematol Oncol Clin North Am       Date:  1999-10       Impact factor: 3.722

2.  Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.

Authors:  F Boulad; A Gillio; T N Small; D George; V Prasad; J Torok-Castanza; A D Regan; N Collins; A D Auerbach; N A Kernan; R J O'Reilly
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

3.  Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome.

Authors:  Philippe Guardiola; Gérard Socié; Xiaxin Li; Patricia Ribaud; Agnés Devergie; Hélène Espérou; Patrice Richard; Richard Traineau; Anne Janin; Eliane Gluckman
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

Review 4.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

5.  A 20-year perspective on the International Fanconi Anemia Registry (IFAR).

Authors:  David I Kutler; Bhuvanesh Singh; Jaya Satagopan; Sat Dev Batish; Marianne Berwick; Philip F Giampietro; Helmut Hanenberg; Arleen D Auerbach
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

6.  Cancer incidence in persons with Fanconi anemia.

Authors:  Philip S Rosenberg; Mark H Greene; Blanche P Alter
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

7.  Bone marrow transplantation for Fanconi anemia.

Authors:  E Gluckman; A D Auerbach; M M Horowitz; K A Sobocinski; R C Ash; M M Bortin; A Butturini; B M Camitta; R E Champlin; W Friedrich; R A Good; E C Gordon-Smith; R E Harris; J P Klein; J J Ortega; R Pasquini; N K Ramsay; B Speck; M R Vowels; M J Zhang; R P Gale
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113

8.  High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia.

Authors:  David I Kutler; Arleen D Auerbach; Jaya Satagopan; Philip F Giampietro; Sat Dev Batish; Andrew G Huvos; Andy Goberdhan; Jatin P Shah; Bhuvanesh Singh
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-01

9.  Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study.

Authors:  A Butturini; R P Gale; P C Verlander; B Adler-Brecher; A P Gillio; A D Auerbach
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

Review 10.  Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome.

Authors:  E Gluckman; J E Wagner
Journal:  Bone Marrow Transplant       Date:  2007-12-17       Impact factor: 5.483

View more
  21 in total

Review 1.  Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Authors:  Christen L Ebens; Margaret L MacMillan; John E Wagner
Journal:  Expert Rev Hematol       Date:  2016-12-21       Impact factor: 2.929

Review 2.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

3.  Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.

Authors:  Christen L Ebens; Todd E DeFor; Rebecca Tryon; John E Wagner; Margaret L MacMillan
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-02       Impact factor: 5.742

4.  Preemptive Bone Marrow Transplantation for FANCD1/BRCA2.

Authors:  Nicholas E Khan; Philip S Rosenberg; Harold P Lehmann; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

5.  Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.

Authors:  Mouhab Ayas; Wael Saber; Stella M Davies; Richard E Harris; Gregory A Hale; Gerard Socie; Jennifer LeRademacher; Monica Thakar; H Joachim J Deeg; Amal Al-Seraihy; Minoo Battiwalla; Bruce M Camitta; Richard Olsson; Rajinder S Bajwa; Carmem M Bonfim; Ricardo Pasquini; Margaret L Macmillan; Biju George; Edward A Copelan; Baldeep Wirk; Abdullah Al Jefri; Anders L Fasth; Eva C Guinan; Biljana N Horn; Victor A Lewis; Shimon Slavin; Polina Stepensky; Marc Bierings; Robert Peter Gale
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

Review 6.  Hematopoietic stem cell transplantation for primary immunodeficiencies.

Authors:  Elizabeth Kang; Andrew Gennery
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-16       Impact factor: 3.722

7.  Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Authors:  Mouhab Ayas; Mary Eapen; Jennifer Le-Rademacher; Jeanette Carreras; Hisham Abdel-Azim; Blanche P Alter; Paolo Anderlini; Minoo Battiwalla; Marc Bierings; David K Buchbinder; Carmem Bonfim; Bruce M Camitta; Anders L Fasth; Robert Peter Gale; Michelle A Lee; Troy C Lund; Kasiani C Myers; Richard F Olsson; Kristin M Page; Tim D Prestidge; Mohamed Radhi; Ami J Shah; Kirk R Schultz; Baldeep Wirk; John E Wagner; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-23       Impact factor: 5.742

Review 8.  The inherited bone marrow failure syndromes.

Authors:  S Deborah Chirnomas; Gary M Kupfer
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

Review 9.  Fanconi anemia.

Authors:  Allison M Green; Gary M Kupfer
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

Review 10.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.

Authors:  Lars U W Müller; David A Williams
Journal:  Mutat Res       Date:  2009-04-02       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.